MedTrace Logo

Prodromal Parkinsonian Features in GBA1 Mutation Carriers

NCT05253560 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 600

Last updated 2026-04-29

No results posted yet for this study

Summary

Objective of the trial. To define a sub-population which is at increased risk of developing Parkinson, beyond the fact of carrying Gaucher; in this sub-population the investigators shall conduct a comprehensive evaluation that includes a variety of non-invasive tests, whose purpose is to evaluate the state of the pre- Parkinson's disease signs, signs which can appear, even twenty years before the appearance of the disease, and also to compare them to a group of diagnosed Gaucher patients and a group of healthy people who are not carriers of Gaucher disease.

A group of those carriers will be available for trial or for treatment, if there will be a medicine for the prevention of the development of Parkinson, obtainable.

Conditions

  • Gaucher Disease, Type 1
  • Healthy

Interventions

DIAGNOSTIC_TEST

The investigators aim to identify prodromal PD in a cohort of carriers of Gaucher disease.

Tests to help identify prodromal PD in a cohort of carriers of Gaucher disease

Sponsors & Collaborators

  • Shaare Zedek Medical Center

    lead OTHER

Principal Investigators

  • Ari Zimran, MD · Shaare Zedek Medical Center

Eligibility

Min Age
40 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-05-16
Primary Completion
2030-01-16
Completion
2030-12-31

Countries

  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05253560 on ClinicalTrials.gov